P Sudre

Prevalence and Risk Factors for Nosocomial Infections in Four University Hospitals in Switzerland

P. Francioli, D. Pittet, S. Harbarth, 1999, Infection Control & Hospital Epidemiology.

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.

S M Marcovina, A. Telenti, V. Mooser, 1999, Circulation.

Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.

A. Telenti, M. Battegay, H. Furrer, 1999, Journal of acquired immune deficiency syndromes.

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.

G H Guyatt, G. Guyatt, L. Griffith, 1999, AIDS.

Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.

A. Telenti, P. Sudre, P Sudre, 2000, AIDS research and human retroviruses.

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

M Egger, A. Telenti, P. Francioli, 1999, JAMA.

Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus.

D. Pittet, O. Rutschmann, S. Harbarth, 1998, Archives of internal medicine.

Tuberculosis: a global overview of the situation today.

A. Kochi, G. T. ten Dam, P. Sudre, 1992, Bulletin of the World Health Organization.